Does Pfizer’s updated anti-coronavirus dose have potential negative repercussions?

The US Centers for Disease Control and Control (CDC) reported on Friday that there may be a safety issue with the bivalent Covid-19 vaccine manufactured by Pfizer and BioNTech, but it is unlikely to be a real danger. Despite this, the agency confirmed that it continues to recommend that everyone receive the vaccine on their respective schedule.

A rapid response analysis revealed that older adults who received a bivalent booster may have an increased risk of ischemic strokes during the first three weeks after receiving the dose, compared to the following weeks, i.e. between the fourth and sixth weeks. The Vaccine Safety Datalink system, which provides data on the safety and effectiveness of vaccines through patients’ electronic health records, detected this possible increase.

Among the nearly 550,000 seniors who got the Pfizer bivalent booster shot and tracked by the Vaccine Safety Datalink system, 130 had a stroke in the three weeks after receiving the dose. No death resulted from the infection among the 130 injured. Dr. William Schaffner, an infectious disease expert at Vanderbilt University, said the number of strokes detected is relatively small, but they represent an alert for further investigation.

The CDC noted that potential confounding factors have been identified in the data from the vaccine surveillance system that may need further investigation. However, the same safety profile has not been disclosed for the use of the moderna bivalent booster dose. The agency also said that Pfizer and other countries using the vaccine did not see any increase in this type of stroke, and this symptom was not detected in any other databases.

The Centers for Disease Control indicated that it does not recommend any change in vaccination practices currently, and that the risks of “Covid-19” to the elderly still outweigh any potential problems related to the safety of the vaccine. The CDC and the Food and Drug Administration will continue to evaluate additional data from these and other vaccine safety systems. This additional data and analysis will be discussed during the upcoming January 26 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee.

Pfizer said in a statement, Friday, that “neither Pfizer, BioNTech, nor the Centers for Disease Control and Control, or the US Food and Drug Administration, have observed similar results across many other monitoring systems approved in the United States and globally.” There is no evidence to conclude that an ischemic stroke is associated with receiving their COVID-19 doses.

The question arises: Does Pfizer’s updated anti-coronavirus dose have potential negative repercussions? The evidence suggests that it is unlikely, however, the CDC and the FDA will continue to monitor the situation and evaluate additional data to make sure the vaccine is as safe as possible.